Agios Announces New Data from Ongoing Phase 1 Trial of AG-221 Showing Robust Clinical Activity in Patients with Advanced Hematologic Malignancies

Agios Announces New Data from Ongoing Phase 1 Trial of AG-221 Showing Robust Clinical Activity in Patients with Advanced Hematologic Malignancies

December 7, 2014

Durable Responses Observed with Patients on Study for up to Eight Months and Ongoing in Advanced Acute Myeloid Leukemia and Other Blood Cancers

Company Expects Global Registration Program to Begin for IDH2 inhibitor AG-221 in 2015 and IDH1 inhibitor AG-120 by early 2016 Agios Announces 2015

Upcoming Milestones for IDH Programs

Pronutria Appoints Dr. Peter Mueller as President of R&D and Chief Scientific Officer

Pronutria Appoints Dr. Peter Mueller as President of R&D and Chief Scientific Officer

December 4, 2014

CAMBRIDGE, Mass., Dec. 4, 2014 /PRNewswire/ -- Pronutria Inc., which is developing novel oral biologics to restore cellular homeostasis in a range of serious medical conditions, announced today that Peter Mueller, Ph.D., has been appointed President of Research and Development and Chief Scientific Officer.  Dr.

TIME's Best Inventions List Also Includes an Edible Invention from Cambridge

TIME's Best Inventions List Also Includes an Edible Invention from Cambridge

November 24, 2014

These foods aren't just convenient and crave-worthy - they could also shrink our environmental footprint.

Last week, TIME published a list of the Best Inventions of 2014 - and while we already covered three noteworthy local companies, we missed a genius gastronomical creation that also happens to hail from Boston.

Seres Health Closes $48 Million Series C Financing

Seres Health Closes $48 Million Series C Financing

December 2, 2014

CAMBRIDGE, Mass., Dec. 2, 2014 /PRNewswire/ -- Seres Health, Inc., a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome, announced today that it has closed its Series C round with $48 million in new investment.

Editas Medicine Licenses Genome Editing Technology from Massachusetts General Hospital

Editas Medicine Licenses Genome Editing Technology from Massachusetts General Hospital

December 1, 2014

Exclusive Agreement Provides Access to Intellectual Property and Technology for a Broad Range of Therapeutic and Agricultural Applications

Editas Medicine Licenses Genome Editing Technology from Duke University

Editas Medicine Licenses Genome Editing Technology from Duke University

December 1, 2014

Exclusive Agreement Provides Access to Intellectual Property and Technology for the Development of Human Therapeutics  

Broad Institute, Harvard, And MIT License CRISPR-Cas9 Technology To Editas Medicine For Therapeutic Applications

Broad Institute, Harvard, And MIT License CRISPR-Cas9 Technology To Editas Medicine For Therapeutic Applications

December 1, 2014

STRATEGIC AGREEMENT ALLOWS FOR ADDITIONAL THERAPEUTIC LICENSING ON A GENE-BY-GENE BASIS

BOSTON and CAMBRIDGE, Mass., Dec. 1, 2014 /PRNewswire-USNewswire/ -- The Broad Institute, Harvard University, the Massachusetts Institute of Technology and Editas Medicine have entered into a worldwide license agreement to grant Editas access to intellectual property related to certain genome editing technology for the development of human therapeutic applications.

Eleven Biotherapeutics Announces Additional Financing of $20 Million

Eleven Biotherapeutics Announces Additional Financing of $20 Million

November 25, 2014

 Proceeds to Supplement Development of Potential Treatments of Moderate to Severe Dry Eye Disease, Moderate to Severe Allergic Conjunctivitis and Diabetic Macular Edema

BIND Therapeutics Presents Positive Phase 2 Results Highlighting Potential of BIND-014 as Novel Anti-Cancer Treatment at Q3W Dosing Schedule for Patients with Non-small Cell Lung Cancer at 26th EORTC-NCI-AACR Annual Symposium

BIND Therapeutics Presents Positive Phase 2 Results Highlighting Potential of BIND-014 as Novel Anti-Cancer Treatment at Q3W Dosing Schedule for Patients with Non-small Cell Lung Cancer at 26th EORTC-NCI-AACR Annual Symposium

November 19, 2014

 - Phase 2 study met primary objective of showing anti-tumor activity as measured by overall response rate at Q3W dosing schedule -

- Promising anti-tumor activity and survival in patients with KRAS mutant tumors and squamous histology -

Agios Pharmaceuticals Announces Early Phase 1 Data Showing Clinical Activity of AG-120 as a Single Agent in Advanced Acute Myeloid Leukemia (AML)

Agios Pharmaceuticals Announces Early Phase 1 Data Showing Clinical Activity of AG-120 as a Single Agent in Advanced Acute Myeloid Leukemia (AML)

November 18, 2014

 -Significant Clinical Responses and Reduction of 2HG Biomarker Provide Early Validation of Mutant IDH1 as a Therapeutic Target in AML -

-Data Support Initiation of Multiple Expansion Cohorts in the First Half of 2015-